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severity. A modified normal tissue complication probability (NTCP) 
model has been investigated to describe AMT data in radiotherapy 
regimes, both conventional and altered in dose and overall treatment 
time (OTT). We tested the hypothesis that such a model can also be 
applied to identify intolerable treatment and predict AMT and late 
toxicity. NTCP model has been compared with other published 
predictive models to identify schedules that are either tolerable or 
not. The Area Under Curve (AUC) was calculated for all models 
assuming treatment tolerance as the gold standard. NTCP model for 
late effect was also calculated. The correlation between AMT/late 
toxicity and the predicted toxicity rate was assessed by a Pearson 
correlation test. 
Results: The AMT NTCP model was able to distinguish between 
acceptable and intolerable schedules among the data available for the 
study(AUC=0.84,95%CI:0.75-0.92). In the equivalent dose at 
2Gy/fraction(EQD2) versus OTT space, the proposed model shows a 
similar trend to that of models proposed by other Authors, but was 
superior in detecting some intolerable schedules. Moreover, it was 
able to predict the incidence of ≥G3 AMT. A correlation between the 
modified late NTCP model and ≥G3 late toxicity has been found as 
trend (p=0.07). 
Conclusions: The proposed acute NTCP model is able to predict ≥G3 
AMT after HN cancer radiotherapy and could be useful for designing 
altered/ hypofractionated schedules in order to reduce the incidence 
of AMT. Late NTCP model was able to predict late toxicity but 
requires further improvements to increase the predictive power.  
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Purpose/Objective: Current models for toxicity prediction in prostate 
cancer radiotherapy are based on the dose-volume histograms which 
lack of spatial accuracy. The goal is to propose new methods able to 
predict late rectal bleeding following high-dose prostate cancer 
radiotherapy. The aim is to fully exploit the tri-dimensional planned 
Dose Distribution (pDD) to study the correlation with rectal toxicity. 
Materials and Methods: A total of 63 patients having received a dose 
of 80Gy in the prostate by IMRT have been included in the study. 
Twelve of them presented rectal bleeding (> grade 1) at two years. 
Only the 3D pDD within the rectum was analysed. 
Our work has been divided in different steps: 
1. Registration 
Individuals' Computed Tomography (CT) from the planning and pDD 
were elastically registered using the demons algorithm to a single 
coordinate system by combining the CTs and organs delineations.  
2.Training step 
The training step consisted in learning from the data two vector 
subspaces spanning the 3D pDD of patients with toxicity and those of 
patients without toxicity, repectively. The different methods used to 
compute this subspaces have different constraints: orthogonality for 
Principal Component Analysis (PCA), mutual statistical independence 
for Independant Component Analysis (ICA). 
3.Validation 
A new patient was classified by evaluating its distances to this two 
subspaces. We computed the euclidean distance between this patient 
and it orthogonal projector in the two subspaces. Eventually, this 
patient is classified as toxic if the distance (dt) from the subspace 
representing toxic patients is less than the distance from the other 
subspace (dnt).  
4. Classification 
A leave-one-out cross validation and statistical measures - sensitivity 
and specificity - were used to evaluate the classification performance. 
The sensitivity assesses the percentage of toxic patients who are 
correctly identified as having toxicity. The specificity assesses the 
percentage of patients who are correctly identified as not having 
toxicity. 
Results: PCA method classified with 1 sensitivity and 0.76 specificity. 
ICA method allowed to classify perfectly rectal bleeding. Figure 1 
shows the distance represention of each patient for ICA method. Two 
significant clusters were identified. 
  
Conclusions: Our statistical approaches conjointly exploit 3D spatial 
patterns of dose. pDD and late rectal bleeding appear to be 
correlated. However, larger data base of patients will enable to use 
more robust classifiers. Our results will be compared with those 
obtained with existing models (i .e. NTCP).  
   
PD-0496   
Multi-centric learning with a federated IT infrastructure: 
application to 2-year lung-cancer survival prediction 
A. Dekker1, G. Nalbantov1, C. Oberije1, W. Wiessler2, M. Eble3, W. 
Dries4, L. Janvary5, P. Bulens6, B. Krishnapuram2, P. Lambin1 
1GROW School for Oncology and Developmental Biology, Radiation 
Oncology (MAASTRO), Maastricht, The Netherlands  
2Siemens, Medical Solutions, Malvern, USA  
3University Hospital Aachen, Radiotherapy, Aachen, Germany  
4Catharina Hospital, Radiotherapy, Eindhoven, The Netherlands  
5CHU Liege, Radiotherapy, Liege, Belgium  
6Limburg Oncologisch Centrum, Radiotherapy, Hasselt, Belgium  
 
Purpose/Objective: To validate the hypothesis that multi-centric 
learning produces better models than models built on data from 
individual centers only. 
Materials and Methods: We created an IT multi-centric network, 
which connects the databases of 5 clinical centers across 3 European 
countries. The network is a federated database where certain rules 
apply to ensure that data privacy is preserved, data never leaves the 
boundaries of its institution of origin, and secure traffic through 
firewalls is achieved. We then tested whether learning from federated 
data via the network gives advantage over single-center learning in 
the following way. A dataset 322 non-operable and non-metastatic 
non-small cell lung cancer patients treated with definite 
(chemo)radiotherapy was distributed with unequal proportions across 
5 centers.A model was built for each center using only the locally 
available data. A distributed learning model was deployed in the IT 
network which has a read-only, no-copy assess to local data. The 
chosen model was the Support Vector Machines (SVM) classifier, solved 
with the Alternating Direction Method of Multipliers method, which 
enables learning from data stored in different locations in a 
distributed way. The biggest advantage of this method is that the 
model learnt from scattered data across centers is exactly the same 
as if the data was centrally available. 
Results: The 5 centers had the following number of lung cancer 
patients available in the infrastructure: 186, 52, 45, 7 and 32, 
respectively. The predicted variable was 2-year survival, with 
predictor variables gender, World Health Organization performance 
status, forced expiratory volume in 1 second, number of positive 
lymph node stations, gross tumor volume and biologically-equivalent 
(at 2 Gray) total dose. No survival data was censored. We used the 
data at center 1 as an external validation set within the network. 
Model performance was evaluated using the area under the receiver 
operating characteristic curve (AUC). Models built separately on 
centers 2 to 5 had AUC's of 0.75, 0.68, 0.61 and 0.72 when validated 
on center 1. The AUC values fluctuate substantially, which reflects to 
a high degree the current model-learning reality and leaves open the 
question of how a combined-data model would perform. We can 
answer this question using the network: the distributed SVM model 
built on all data from centers 2 to 5 without any data leaving its origin 
had an AUC of 0.77 on center 1 (see Figure 1). 
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Conclusions: The access to federated multi-centric data enables 
creating more reliable and more robust models than those based on 
single-center data. The infrastructure has inherent external validation 
capabilities that are available at virtually no extra cost of time. There 
is therefore an enormous potential of using such kind of infrastructure 
for learning more accurate and reliable medical prediction models in 
the future.  
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Purpose/Objective: To determine a self consistent set of 
radiobiological parameters in prostate cancer. 
Materials and Methods: A method to estimate intrinsic 
radiosensitivity (α), fractionation sensitivity (α/β), repopulation 
doubling time (Td), number of clonogens (N) and kick-off time for 
accelerated repopulation (Tk) of prostate cancer, has been developed. 
Based on the generalized linear quadratic model (LQ) and without 
assuming the iso-effective hypothesis, the potential applications of 
the method were investigated using the clinical outcome of the 
biochemical relapse free survival (bRFS) recently reviewed in 
literature. The strength and limitation of the method, regarding the 
fitted parameters and 95% confidence intervals, are also discussed. 
Results: Our best estimate of α/β is 2.96 Gy (2.41-3.53)95%. The 
correspondent α valueis 0.16 Gy-1 (0.14-0.18)95% which is compatible 
with a realistic number of clonogens: 6.5·106 (1.5·106-2.1·107)95%. The 
estimated cell doubling time Td is 5.1 days (4.2-7.2)95%, very low if 
compared to that reported in literature. This corresponds to the dose 
required to offset the repopulation occurring in one day (Dprolif) of 
0.51 Gy/day (0.32-0.68)95%. However, a long kick-off time Tk of 31 
days (22-41)95% from the start of radiotherapy was found. 
Conclusions: The proposed analytical/graphical method has allowed 
to fit clinical data providing a self-consistent set of radiobiological 
parameters for prostate cancer. With our analysis we confirm a low 
value for α/β with a correspondingly high value of intrinsic 
radiosensitivity, a realistic average number of clonogens, a long kick-
off time for accelerated repopulation and a surprisingly fast 
repopulation that suggests the involvement of subpopulations of 
specifically tumorigenic stem cells during the continuing radiotherapy. 
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Purpose/Objective: Standardized Total Average Toxicity (STAT) score 
was proposed by Barnett (IJROBP11) as a global score which may be 
used to:  
(a) facilitate the analysis of overall radiation (RT) toxicity (tox) 
(b) pool data from multiple trials (in order to increase statistical 
power) 
(c) select patients (pts) to be included in studies of possible genetic 
determinants of RT tox. 
In the same paper application of STAT to 2 cohorts of breast cancer 
pts was presented. 
We here evaluate application of STAT to 2 prostate cancer populations 
(A and B), with the aim of verifying that STAT keeps all known 
correlations of single tox endpoints with clinical/dosimetric risk 
factors and to select possible radiosensitive pts 
Materials and Methods: Population A (646 pts, doses 70-80Gy,1.8-
2Gy/fr) was included in a prospective trial on rectal tox (recorded by 
questionnaires). 
Population B (179 pts, doses 60-80Gy,1.8-2.65Gy/fr) was included in a 
prospective trial on genito-urinary tox (measured by IPSS). STAT 
calculation was made following definition by Barnett. Key point is that 
STAT defines whether a pt’s global tox is high or low relative to the 
distribution of the global tox of other pts. STAT measures the distance 
between the single pt and the average of all considered pts in terms 
of standard deviations.  
For population A, 2 STATs were considered: baseline STAT (BSTAT) 
and late (3yrs follow-up) STAT (STATGI). For population B, only acute 
tox was available and acute STAT (STATGU) was calculated. We 
considered pts with STATGI/STATGU>0.8 as exhibiting high tox with 
respect to the whole cohort and clinical/dosimetric predictors of 
STATGI/STATGU>0.8 were determined through multivariable logistic 
analysis. Analysis of residuals was used to individuate the 
radiosensitive cohorts 
Results: STATGI>0.8 (43/646pts) was predicted by: BSTAT (continuous 
variable (cv), OR=2, p=0.04), previous diseases of the colon (OR=3, 
p=0.02), the % volume of rectum receiving more than 40Gy (V40Gy, 
cv, OR=1.02, p=0.08) and V75Gy (cv, OR=1.05, p=0.03). Overall 
p=0.0006, AUC 0.74. 
STATGU>0.8 (39/179pts) was predictedby: pre-RT IPSS (cv, OR=1.14, 
p=0.0008), Body Max Index (cv, OR=0.94, p=0.2), clinical T3 stage 
(OR=2, p=0.1), absolute bladder surface receiving ≥8.5 Gy/week (cv, 
OR=1.014, p=0.03) and absolute bladder surface receiving ≥12.5 
Gy/week (cv, OR=1.035, p=0.06). Overall p<0.0001, AUC 0.81. 
From analysis of residuals, 14 and 11 pts emerged as possible 
radiosensitive pts (with high STAT which is not predicted from model) 
for STATGI and STATGU, respectively. 
 
 
Conclusions: Correlation between high STATGI/STATGU and 
clinical/dosimetric risk factors confirmed previously results found in 
the 2 populations for the single tox endpoints. 
This global approach allows objective identification of pts whose tox 
are not explained by the global model and who may be included in 
studies of possible genetic determinants of RT tox 
 
 
 
 
